In conclusion, our study reports the following novel findings: (1) Dual targeting of both tGLI1 and IL-6/IL-6R/GP130 signaling pathways synergize to suppress HER2-enriched breast cancer and TNBC in vitro. Here, ERBB2 is linked to breast carcinoma.